ArticleOncology letters2018
Targeting breast cancer cells with a CuInS
Article in Oncology letters, 2018. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 8 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
8 citing papers in PubMed, 1 synthesis or guideline pooled it, 24 citations in OpenAlex.
- Current perspectives and trends in nanoparticle drug delivery systems in breast cancer: bibliometric analysis and review.Frontiers in bioengineering and biotechnology · 2023Pooled it
- Bioinspired quantum dots: advancing diagnostic and therapeutic strategies in breast cancer.RSC advances · 2025Review
- Applicability of Quantum Dots in Breast Cancer Diagnostic and Therapeutic Modalities-A State-of-the-Art Review.Nanomaterials (Basel, Switzerland) · 2024Review
- Quantum Dot Research in Breast Cancer: Challenges and Prospects.Materials (Basel, Switzerland) · 2024Review
- Highly sensitive detection of dengue biomarker using streptavidin-conjugated quantum dots.Scientific reports · 2021Article
- Nanoparticle-mediated targeted drug delivery for breast cancer treatment.Biochimica et biophysica acta. Reviews on cancer · 2019Review
- Development of a low-cost and portable smart fluorometer for detecting breast cancer cells.Biomedical optics express · 2019Article
- Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors at 3 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
The aim of the present study was to develop a water-soluble biomarker for the detection of breast cancer using quantum dots (QDs) conjugated to Ki-67, a nuclear protein associated with the cell cycle. Ki-67 is also a marker of cell proliferation, with expression levels categorizing good and poor prognosis in invasive breast cancer. Ki-67 is a clinically used biomarker for breast cancer diagnosis, treatment and prognosis. Owing to the optical and chemical advantages of QDs, QD-based nanotechnology may aid the construction of a biomedical imaging platform for the study of cancer cell behavior. In the present study, a biomarker was prepared by employing the water-soluble CuInS
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.